Navigation Links
Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/18/2009

SEATTLE, May 18 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) today announced upcoming presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29-June 2, 2009 in Orlando, Florida. Abstracts related to our product candidates Stimuvax(R), PX-866 and PX-12 are now available to the public online at the ASCO Web site, www.abstract.asco.org.

    Abstracts include:

    -   "Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients
        (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)"

        - Abstract No: 3055 Poster session: Developmental Therapeutics:
        Immunotherapy - Saturday May 30, 8:00 AM to 12:00 PM, Level 2,
        West Hall C

    -   "Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K)
        inhibitor"

        - Abstract No: 3542 Poster session: Developmental Therapeutics:
        Molecular Therapeutics - Saturday May 30, 8:00 AM to 12:00 PM
        Level 2, West Hall C

    -   "Results from phase Ib studies of PX-12, a thioredoxin inhibitor in
        patients with advanced solid malignancies"

        - Abstract # 2571, Poster Session: Developmental Therapeutics:
        Cytotoxic Chemotherapy - Saturday May 30, 8:00 AM to 12:00 PM,
        Level 2, West Hall C

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

Forwa
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Oncothyreon highlights corporate and clinical objectives for 2008
3. Oncothyreon to present at BIO CEO & Investor Conference
4. Oncothyreon launches new corporate website
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon announces effectiveness of shelf registration statement
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 2015  Adaptive Biotechnologies today announced publication of ... Oncology showing that analysis of circulating tumor ... residual disease (MRD) detection and quantification technology (available ... patients with diffuse large B-cell lymphoma (DLBCL) who ... usually several months before disease can be detected ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 ... (AFM) was selected to receive the prestigious “Best ... Economy Magazine.    Park NX10 is the premium research-grade True ... Z scanner linearity, closed-loop detector noise, and minimized ... SmartSca n, which allows images with a ...
(Date:4/1/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC ... to announce that Biohaven Pharmaceutical Holding Company Limited ... into an agreement with inVentiv Health for the ... their lead compound (BHV-0223). Biohaven ... clinical stage neuroscience compounds targeting the glutamatergic system. ...
(Date:4/1/2015)... 2015  Among 1,050 U.S. consumers, the majority knows ... percent) and only 36 percent reported being screened for ... findings from a survey released today by  ... developer of solutions that aid in the early detection ... polled 1,050 U.S. consumers on their knowledge of risk ...
Breaking Biology Technology:Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 3Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 4Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 5Park Systems Awarded the New Economy Magazine “Best Analytic Instrumentation Company 2014” 2Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 2National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 4
... and OMX Nordic Exchange: EPCT) today announced that ... be presenting at the IBC conference,on Assays and ... San Diego, CA,on October 17, 2007. Dr. Drewe ... discovery efforts targeting the Myc oncogene pathway,utilizing EpiCept,s ...
... NEW YORK, Oct. 15 Senex Biotechnology, Inc. ... at the 8th International,Conference on Alzheimer,s Disease Drug ... of Senex, described the identification of the first,drug ... amounts of,several proteins involved in Alzheimer,s disease, including: ...
... Therapeutics, Inc.,has named Jeffrey N. Fellows, a biotechnology ... regulatory experience, as Vice President,of Regulatory Affairs. ... PhD, said,"Jeff is a great addition to our ... clinical trials applications, regulatory compliance and,interactions with the ...
Cached Biology Technology:EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 2EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 3EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 4EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 5Senex Biotechnology Announces Presentation of Alzheimer's Disease Drug Discovery Effort 2Senex Biotechnology Announces Presentation of Alzheimer's Disease Drug Discovery Effort 3Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs 2
(Date:3/26/2015)... The Granite Club, Canada,s ... announced it has implemented a state-of-the-art access and security ... and staff, while restricting access to authorized users only. ... IMID Access system because it has the perfect combination ... in addition to unparalleled security," said James DiRenzo ...
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs ... management company, today announced that the Company will demonstrate ... both enterprise and consumers at Connect:ID on March 23 ... HOYOS Labs will highlight the IEEE Biometric Open ... ; and enterprise access control system. BOPS was ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... Service and the Southern Group of State Foresters released the ... Tuesday, May 17, which identifies areas forest managers will focus ... According to the report, urbanization, bioenergy use, weather patterns, ... South,s forests between the years 2010 and 2060. About ...
... be nutritional powerhouses, but some types are no match ... "mummy berry" disease. Fortunately, U.S. Department of Agriculture ... in blueberry breeding and cultivation. Geneticist Mark Ehlenfeldt and ... They work for USDA,s Agricultural Research Service (ARS). ...
... have been reviewing the family-group names in several major ... works is to provide a foundation of valid, accepted ... taxa, facilitate decisions on priority, promote long-term stability of ... transition of taxonomy into the digital age. A ...
Cached Biology News:Forest Service unveils first comprehensive forecast on southern forests 2Forest Service unveils first comprehensive forecast on southern forests 3